Cardiovascular Mortality

Also known as: Cardiovascular Death / Cardiac Death

DrugDrug NameDrug Description
DB00945Acetylsalicylic acidAlso known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) [FDA label]. Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer [A177325]. Aspirin is classified as a _non-selective cyclooxygenase (COX) inhibitor_ [A32682, A177268] and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others [L5968]. Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants [FDA label].
DB08907CanagliflozinCanagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type 2 diabetes mellitus [L5897], [FDA label]. Canagliflozin is the first oral antidiabetic drug approved for the prevention of cardiovascular events in patients with type 2 diabetes [L5897]. Cardiovascular disease is the most common cause of death in these patients [A177083].
DB00571PropranololA widely used non-cardioselective beta-adrenergic antagonist. Propranolol is used in the treatment or prevention of many disorders including acute myocardial infarction, arrhythmias, angina pectoris, hypertension, hypertensive emergencies, hyperthyroidism, migraine, pheochromocytoma, menopause, and anxiety.
DB00015ReteplaseHuman tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. Retavase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from retavase - kringle-1, finger, and epidermal growth factor (EGF).
DB06228RivaroxabanRivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, 2011.
DB00177ValsartanValsartan is an angiotensin-receptor blocker (ARB) that may be used to manage hypertension and heart failure. Many studies have demonstrated the efficacy of valsartan in reducing blood pressure (BP) in many patient populations (including elderly, women, children, obese patients, patients with diabetes mellitus, patients with chronic kidney disease (CKD), patients at high risk of cardiovascular (CV) disease, African Americans, Hispanic Americans and Asians) and in improving the clinical outcome in cardiovascular (CV) disease and chronic kidney disease (CKD) [A174124]. Valsartan was initially approved in 1996 in Europe for the treatment of hypertension in adults. Shortly after, in 1997, this drug was approved in the United States [A174124]. This drug is generally well-tolerated with a side-effect profile superior to that of other antihypertensive drugs [A174130], [A174133].
DrugDrug NameTargetType
DB00945Acetylsalicylic acidProstaglandin G/H synthase 1target
DB00945Acetylsalicylic acidProstaglandin G/H synthase 2target
DB00945Acetylsalicylic acidAldo-keto reductase family 1 member C1target
DB00945Acetylsalicylic acidSolute carrier family 22 member 6transporter
DB00945Acetylsalicylic acidMultidrug resistance protein 1transporter
DB00945Acetylsalicylic acidCytochrome P450 2C19enzyme
DB00945Acetylsalicylic acidCytochrome P450 2C9enzyme
DB00945Acetylsalicylic acid5'-AMP-activated protein kinasetarget
DB00945Acetylsalicylic acidEndothelin-1 receptortarget
DB00945Acetylsalicylic acidNuclear factor kappa b beta subunittarget
DB00945Acetylsalicylic acidCellular tumor antigen p53target
DB00945Acetylsalicylic acid78 kDa glucose-regulated proteintarget
DB00945Acetylsalicylic acidRibosomal protein S6 kinase alpha-3target
DB00945Acetylsalicylic acidNF-kappa-B inhibitor alphatarget
DB00945Acetylsalicylic acidTumor necrosis factor-inducible gene 6 proteintarget
DB00945Acetylsalicylic acidCaspase-1target
DB00945Acetylsalicylic acidCaspase-3target
DB00945Acetylsalicylic acidInhibitor of nuclear factor kappa-B kinase subunit betatarget
DB00945Acetylsalicylic acidExtracellular signal-regulated kinase (ERK)target
DB00945Acetylsalicylic acidG1/S-specific cyclin-D1target
DB00945Acetylsalicylic acidMyc proto-oncogene proteintarget
DB00945Acetylsalicylic acidProliferating cell nuclear antigentarget
DB00945Acetylsalicylic acidCyclin Atarget
DB00945Acetylsalicylic acidUDP-glucuronosyltransferase 1-6enzyme
DB00945Acetylsalicylic acidArylamine N-acetyltransferase 2enzyme
DB00945Acetylsalicylic acidSolute carrier family 22 member 8transporter
DB08907CanagliflozinUDP-glucuronosyltransferase 1-9enzyme
DB08907CanagliflozinUDP-glucuronosyltransferase 2B4enzyme
DB08907CanagliflozinCytochrome P450 3A4enzyme
DB08907CanagliflozinSodium/glucose cotransporter 2target
DB08907CanagliflozinMultidrug resistance protein 1transporter
DB08907CanagliflozinCanalicular multispecific organic anion transporter 1transporter
DB08907CanagliflozinAlpha-1-acid glycoprotein 1carrier
DB08907CanagliflozinATP-binding cassette sub-family G member 2transporter
DB00571PropranololBeta-1 adrenergic receptortarget
DB00571PropranololBeta-2 adrenergic receptortarget
DB00571PropranololBeta-3 adrenergic receptortarget
DB00571Propranolol5-hydroxytryptamine receptor 1Atarget
DB00571Propranolol5-hydroxytryptamine receptor 1Btarget
DB00571PropranololCytochrome P450 1A2enzyme
DB00571PropranololCytochrome P450 2D6enzyme
DB00571PropranololAlpha-1-acid glycoprotein 1carrier
DB00571PropranololCytochrome P450 2C19enzyme
DB00571PropranololCytochrome P450 3A4enzyme
DB00571PropranololCytochrome P450 3A5enzyme
DB00571PropranololCytochrome P450 3A7enzyme
DB00571PropranololSolute carrier family 22 member 2transporter
DB00571PropranololMultidrug resistance protein 1transporter
DB00571PropranololCytochrome P450 1A1enzyme
DB00571PropranololAmine oxidase [flavin-containing] Aenzyme
DB00015ReteplaseUrokinase plasminogen activator surface receptortarget
DB00015ReteplaseFibrinogen alpha chaintarget
DB00015ReteplasePlasminogen activator inhibitor 1target
DB06228RivaroxabanCoagulation factor Xtarget
DB06228RivaroxabanCytochrome P450 3A4enzyme
DB06228RivaroxabanCytochrome P450 2J2enzyme
DB06228RivaroxabanMultidrug resistance protein 1transporter
DB06228RivaroxabanCytochrome P450 3A5enzyme
DB06228RivaroxabanATP-binding cassette sub-family G member 2transporter
DB00177ValsartanType-1 angiotensin II receptortarget
DB00177ValsartanCytochrome P450 2C9enzyme
DB00177ValsartanSolute carrier organic anion transporter family member 1B3transporter
DB00177ValsartanSolute carrier organic anion transporter family member 1B1transporter
DB00177ValsartanCanalicular multispecific organic anion transporter 1transporter
DrugDrug NamePhaseStatusCount
DB01373CalciumNot AvailableCompleted1
DB06724Calcium CarbonateNot AvailableCompleted1
DB00658SevelamerNot AvailableCompleted1